---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-015205"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:50:18.340980+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ardelyx Q1 IBSRELA sales $11.4M, net loss $26.8M; XPHOZAH NDA resubmitted

## Summary
- IBSRELA net product sales $11.4M in Q1 2023, up from $0.5M in Q1 2022.
- Net loss $26.8M ($0.13/share) vs $28.1M ($0.21/share) in prior-year period.
- Cash and investments $130.4M as of March 31, 2023; raised $51.9M from ATM offering.
- XPHOZAH NDA resubmitted to FDA on April 17, 2023 for phosphate control in CKD patients on dialysis.
- Licensed TGR5 agonist portfolio to METiS Therapeutics for $750K upfront + up to $243M milestones.

## SEC filing metadata
- accession: 0001628280-23-015205
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828023015205/0001628280-23-015205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828023015205/ardx-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-015205
- JSON: https://secwatch.observer/filing/0001628280-23-015205.json
- Plain text: https://secwatch.observer/filing/0001628280-23-015205.txt

## Key facts
- Earnings Releases
  ARDELYX, INC. reported the quarter ended March 31, 2023 results: revenue $11.4 million, net income $26.8 million, EPS $(0.13) per share.
  - Period: the quarter ended March 31, 2023
  - Revenue: $11.4 million
  - Net income: $26.8 million
  - EPS: $(0.13) per share
  - Result: reported results
  source text: EX-99.1 (EX-99.1) --- Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million XPHOZAH New Drug Application resubmitted on April 17, 2023 Company ends Q1 with over $130 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time
  evidence_url: https://www.sec.gov/Archives/edgar/data/1437402/000162828023015205/0001628280-23-015205-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.